CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
CBIO
54 hedge funds and large institutions have $46.6M invested in Crescent Biopharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 13 closing their positions.
Holders
54
Holders Change
+6
Holders Change %
+12.5%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
14
Reduced
10
Closed
13
Calls
$721K
Puts
$607K
Net Calls
+$114K
Net Calls Change
-$924K
Top Buyers
1 |
AG
1
Artal Group
Luxembourg
|
$10.8M |
2 |
OCA
2
Octagon Capital Advisors
New York
|
$3.78M |
3 |
3
Axa
Paris,
France
|
$2.03M |
4 |
4
Goldman Sachs
New York
|
$1.14M |
5 |
5
Two Sigma Advisers
New York
|
$749K |